Psychedelics, Psychedelic-Assisted Therapy and Employees’ Wellbeing
Charlie Smith
Journal of Management Inquiry August 28, 2024 DOI: 10.1177/10564926241267208 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Psychedelic-assisted therapy |
| Keywords | Psychedelic therapy:psychedelic-assisted therapy Breakthrough therapy Corporate wellness Employee health Work participation Occupational health Psychological well-being Mental wellness Workplace integration:corporate adoption Organizational implementation Employment impact Economic impact |
| Citations | 1 |
| Key findings | Management research on economic analyses, employee wellbeing, and stigma could influence policymakers' decisions and support employees undergoing psychedelic-assisted therapy. |
Abstract
There is a psychedelic renaissance with key drugs that alter perception and mood being given breakthrough therapy status as potential treatments for common mental health conditions. If approved, these drugs may be used alongside psychedelic-assisted therapy (PAT), a therapeutic process supporting learning from taking psychedelics. Nearly 100 companies, mainly across America, Canada, Europe, and Australia, are developing compounds such as psilocybin and lysergic acid diethylamide. This article considers the management research that could influence policymakers’ decisions and support employees undergoing PAT. Firstly, research on economic analyses that could inform policymakers’ approval decisions is outlined. Secondly, research exploring PAT's influence on employees’ wellbeing is noted. Thirdly, research on employees’ experiences of stigma around mental health, psychedelics and PAT is suggested. Developing these inquiries may influence employees’ PAT success and improve global mental health by encouraging successful work participation as a critical determinant of mental wellness.
Comparable studies
Other narrative reviews on psychedelic-assisted therapy, most cited first.
Citations in the library
Cites 20
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine November 3, 2022
- Increased global integration in the brain after psilocybin therapy for depression. Nature Medicine April 11, 2022
- MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nature Medicine October 1, 2023
- Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology December 25, 2017
- Psychedelic Psychiatry's Brave New World. Cell April 1, 2020
and 15 more in the library